Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 515

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy

Open access
Chen, Yunching, Zhu, Xiaodong, Zhang, Xiaoju, Liu, Bin, Huang, Leaf·2010·Molecular Therapy
DOI 10.1038/mt.2010.136
Open this paper in CoChat — free account

Abstract

Targeted delivery of RNA-based therapeutics for cancer therapy remains a challenge. We have developed a LPH (liposome-polycation-hyaluronic acid) nanoparticle formulation modified with tumor-targeting single-chain antibody fragment (scFv) for systemic delivery of small interfering RNA (siRNA) and microRNA (miRNA) into experimental lung metastasis of murine B16F10 melanoma. The siRNAs delivered by the scFv targeted nanoparticles efficiently downregulated the target genes (c-Myc/MDM2/VEGF) in the lung metastasis. Two daily intravenous injections of the combined siRNAs in the GC4-targeted nanoparticles significantly reduced the tumor load in the lung. miRNA-34a (miR-34a) induced apoptosis, inhibited survivin expression, and downregulated MAPK pathway in B16F10 cells. miR-34a delivered by the GC4-targeted nanoparticles significantly downregulated the survivin expression in the metastatic tumor and reduced tumor load in the lung. When miR-34a and siRNAs were co-formulated in GC4-targeted nanoparticles, an enhanced anticancer effect was observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2010.136

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 27

  1. Castanotto, 2009, The promises and pitfalls of RNA-interference-based therapeutics, Nature, 457, 426, 10.1038/nature07758 · DOI · Paper page
  2. Coburn, 2003, siRNAs: a new wave of RNA-based therapeutics, J Antimicrob Chemother, 51, 753, 10.1093/jac/dkg166 · DOI
  3. Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702 · DOI · Paper page
  4. Li, 2008, Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA, Mol Ther, 16, 942, 10.1038/mt.2008.51 · DOI · Paper page
  5. Gou, 2007, Primer extension-based method for the generation of a siRNA/miRNA expression vector, Physiol Genomics, 31, 554, 10.1152/physiolgenomics.00005.2007 · DOI
  6. Yan, 2009, MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met, Invest Ophthalmol Vis Sci, 50, 1559, 10.1167/iovs.08-2681 · DOI · Paper page
  7. Li, 2009, MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes, Cancer Res, 69, 7569, 10.1158/0008-5472.CAN-09-0529 · DOI · Paper page
  8. Welch, 2007, MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells, Oncogene, 26, 5017, 10.1038/sj.onc.1210293 · DOI · Paper page
  9. Hammond, 2006, MicroRNA therapeutics: a new niche for antisense nucleic acids, Trends Mol Med, 12, 99, 10.1016/j.molmed.2006.01.004 · DOI
  10. Li, 2008, Tumor-targeted delivery of siRNA by self-assembled nanoparticles, Mol Ther, 16, 163, 10.1038/sj.mt.6300323 · DOI · Paper page
  11. Chen, 2009, Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells, Mol Pharm, 6, 696, 10.1021/mp800136v · DOI
  12. Zhu, 2009, Identification of internalizing human single chain antibodies targeting brain tumor sphere cells, Mol Cancer Ther
  13. Xia, 2006, Construction of human ScFv phage display library against ovarian tumor, J Huazhong Univ Sci Technol Med Sci, 26, 497, 10.1007/s11596-006-0502-y · doi:10.1007/s11596-006-0502-y
  14. Tsantili, 1999, High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor, J Neuroimmunol, 94, 15, 10.1016/S0165-5728(98)00195-7 · doi:10.1016/s0165-5728(98)00195-7
  15. Chen, 2009, Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure, Med Oncol, 26, 491, 10.1007/s12032-008-9161-0 · doi:10.1007/s12032-008-9161-0
  16. Takeuchi, 2005, Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine, Int J Cancer, 117, 1032, 10.1002/ijc.21267 · DOI
  17. Fecher, 2008, The MAPK pathway in melanoma, Curr Opin Oncol, 20, 183, 10.1097/CCO.0b013e3282f5271c · DOI · Paper page
  18. Li, 2009, miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells, Cancer Lett, 275, 44, 10.1016/j.canlet.2008.09.035 · DOI · Paper page
  19. Tsuchiya, 2006, MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer, J Pharmacol Sci, 101, 267, 10.1254/jphs.CPJ06013X · DOI
  20. Ruvkun, 2006, Clarifications on miRNA and cancer, Science, 311, 36, 10.1126/science.311.5757.36d · doi:10.1126/science.311.5757.36d
  21. Chono, 2008, An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor, J Control Release, 131, 64, 10.1016/j.jconrel.2008.07.006 · DOI · Paper page
  22. Ruan, 2006, Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection, Mol Cell Proteomics, 5, 2364, 10.1074/mcp.M600246-MCP200 · DOI
  23. An, 2008, Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies, Mol Cancer Ther, 7, 569, 10.1158/1535-7163.MCT-07-2132 · DOI
  24. Bidlingmaier, 2009, Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma, Cancer Res, 69, 1570, 10.1158/0008-5472.CAN-08-1363 · DOI
  25. Conrad, 2009, Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion, J Mol Med, 87, 507, 10.1007/s00109-009-0446-3 · doi:10.1007/s00109-009-0446-3
  26. Liu, 2004, Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells, Cancer Res, 64, 704, 10.1158/0008-5472.CAN-03-2732 · DOI
  27. Roth, 2007, Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells, Mol Cancer Ther, 6, 2737, 10.1158/1535-7163.MCT-07-0140 · DOI

Cited by

See all 515

Metadata

Authors
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2010-09
Volume
18
Issue
9
Pages
1650-1656
ISSN
1525-0016 (ISSN-L)
DOI
10.1038/mt.2010.136
OpenAlex
W1972461780
Cited by
515
References
1
FWCI
16.90
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy. https://app.cochat.ai/papers/10.1038/mt.2010.136
The paper
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010). Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy. Molecular Therapy. https://doi.org/10.1038/mt.2010.136

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.